2025 annual financial data

Iovance Biotherapeutics 2025 Net margin

Direct answer

Net margin was -148.38%.

Operating income was -403,356,000 USD and net income was -390,978,000 USD.
Operating cash flow was -302,408,000 USD.

Get free Iovance Biotherapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Revenue
263,502,000 USD
Operating income
-403,356,000 USD
Net income
-390,978,000 USD
Operating cash flow
-302,408,000 USD